Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Fourth Interim Analysis of the Hem Powr Study: A Post Hoc Analysis of Real-World Effectiveness and Safety of Damoctocog Alfa Pegol in Adolescent and Older Patients with Hemophilia a

Mark T Reding, María Teresa Alvarez-Román, Giancarlo Castaman, Maissaa Janbain, Tadashi Matsushita, Karina Meijer, Kathrin Schmidt, Johannes Oldenburg

Blood (2024) 144 (Supplement 1): 3968.

https://doi.org/10.1182/blood-2024-205121

Published: 2024

Journal Articles

Real-World Patterns of Additional Factor Treatment Use Among Hemophilia a Patients on Regular Prophylaxis in the United States: Results from the Picnichealth Database

Jonathan C. Roberts, Angela C Weyand, Mark T Reding, Nana Kragh, Nicole Tsao, Emily Cibelli, Gillian Hanson, Duygu Bozkaya, Anne-Laure Tardy

Blood (2024) 144 (Supplement 1): 3967.

https://doi.org/10.1182/blood-2024-204580

Published: 2024

Journal Articles

Become-9: A Phase 1/2 Dose Escalation and Expansion Study of be-101 for the Treatment of Adults with Moderately Severe or Severe Hemophilia B

Steven W. Pipe, Mark T Reding, Bryan Chin, Karen Campbell, Hanlan Liu, Wing Yen Wong

Blood (2024) 144 (Supplement 1): 2593.1.

https://doi.org/10.1182/blood-2024-208733

Published: 2024

Journal Articles

Interim Subgroup Analysis of the Effectiveness and Safety of Damoctocog Alfa Pegol Prophylaxis in Previously Treated Patients with Hemophilia A Treated Every 5 or Every 7 Days: Results from the Real-World Observational HEM-POWR Study

Mark T Reding, María Teresa Alvarez Román, Martin Sanabria, Giancarlo Castaman, Maissaa Janbain, Tadashi Matsushita, Karina Meijer, Kathrin Schmidt, Johannes Oldenburg

Blood (2022) 140 (Supplement 1): 5612–5614.

https://doi.org/10.1182/blood-2022-169159

Published: 2022

Journal Articles

Eptacog Beta Efficacy in Treating Mild or Moderate Bleeds in Target Joints of Individuals with Hemophilia A or B and Inhibitors in PERSEPT 1

Blood (2022) 140 (Supplement 1): 5597–5599.

https://doi.org/10.1182/blood-2022-156110

Published: 2022

Journal Articles

A Preliminary Analysis of Athn 16: Safety of Coagulation Factor VIIa (recombinant)-Jncw for the Treatment of Bleeding Events in Patients with Congenital Hemophilia a or B with Inhibitors

Tammuella Chrisentery-Singleton, Lauren E. Amos, Daniel Bonzo, Miguel Escobar, Adam Giermasz, Emmanuelle Lagrue, Christine Knoll, Sonia Nasr, Michael Recht, Spencer Sullivan, Doris V. Quon, Mark T. Reding

Blood (2022) 140 (Supplement 1): 11360–11361.

https://doi.org/10.1182/blood-2022-163372

Published: 2022

Journal Articles

Relationship between Endogenous, Transgene FVIII Expression and Bleeding Events Following Valoctocogene Roxaparvovec Gene Transfer for Severe Hemophilia A: A Post-Hoc Analysis of the GENEr8-1 Phase 3 Trial

Blood (2021) 138 (Supplement 1): 3972.

https://doi.org/10.1182/blood-2021-144508

Published: 2021

Journal Articles

PREDICT: A Multicenter, Prospective, Open-Label, Clinical Study Using a New Risk Score Approach to Assess the Most Appropriate Prophylaxis Regimen to Reach Favorable Outcomes in Hemophilia A, When Switching from Standard-Half-Life Products to Damoctocog Alfa Pegol

Guy Young, Mark T Reding, Robert F. Sidonio, Jr., Doris V. Quon, Janice M. Staber, Cindy A. Leissinger, Jessica Charlet, Moncef Boukerrou

Blood (2021) 138 (Supplement 1): 2115.

https://doi.org/10.1182/blood-2021-148700

Published: 2021

Journal Articles

Efficacy and Safety of Bay 94-9027 Is Sustained for 5 Years: Outcomes in 33 Patients in the Protect VIII Extension Study

Mark T. Reding, MD, Lone Hvitfeldt Poulsen, Liu Tian, Dr, Pal André Holme, PhD MD

Blood (2018) 132 (Supplement 1): 2492.

https://doi.org/10.1182/blood-2018-99-114659

Published: 2018

Journal Articles

Decrease in Overall and Joint Bleeding Rates with Extended-Interval Dosing: > 4 Years of Bay 94-9027 Prophylaxis in the Protect VIII Extension

Mark T. Reding, MD, Shadan Lalezari, Dr, Ingrid Pabinger, MD, Monica Maas Enriquez, Dr, Jonathan M. Ducore, MD

Blood (2018) 132 (Supplement 1): 1206.

https://doi.org/10.1182/blood-2018-99-116272

Published: 2018

Journal Articles

Maintaining Perioperative Hemostasis in Patients with Severe Hemophilia A and Inhibitors Receiving Emicizumab Prophylaxis

Karen L. Zimowski, MD, Glaivy M. Batsuli, MD, Mark T. Reding, MD, Jatin Rana, MD, Michael U. Callaghan, MD, Kelly Tickle, MSN, APN, PPCNP-BC, Shannon L. Meeks, MD, Robert F. Sidonio, Jr., MD

Blood (2018) 132 (Supplement 1): 635.

https://doi.org/10.1182/blood-2018-99-115089

Published: 2018

Journal Articles

Barriers to the Effective Diagnosis and Management of a Bleeding Patient with Undiagnosed Bleeding Disorder Across Multiple Specialties: Results of a Quantitative Case-Based Survey.

Mark T. Reding, MD, David L. Cooper, MD, MBA

Blood (2010) 116 (21): 3673.

https://doi.org/10.1182/blood.V116.21.3673.3673

Published: 2010

Journal Articles

Risk Factors for Inhibitor Development in Mild and Moderate Hemophilia A: A Case-Control Study.

Christine L Kempton, MD, MSc, J. Michael Soucie, Ph.D, Connie H. Miller, PhD, Craig Hooper, PhD, Miguel A. Escobar, MD, Mark T. Reding, MD, Alice J. Cohen, MD, Nigel S. Key, MBChB, Arthur R. Thompson, M.D., Ph.D., Marilyn J. Manco-Johnson, Thomas C. Abshire, MD

Blood (2009) 114 (22): 3184.

https://doi.org/10.1182/blood.V114.22.3184.3184

Published: 2009

Journal Articles

Spectrum of Antiphospholipid Antibodies and Associated Thrombotic and Obstetric Events among Patients with Antiphospholipid Syndrome

Mrinal M Patnaik, MD, Kitsada Wudhikarn, M.D., Monal M Shroff, PhD, Anthony A Killeen, MD, Mark T. Reding, MD, Raj S. Kasthuri, MD, MBBS

Blood (2008) 112 (11): 5343.

https://doi.org/10.1182/blood.V112.11.5343.5343

Published: 2008

Journal Articles

A Phase II Open-Label Study Evaluating Hemostatic Activity, Pharmacokinetics and Safety of Recombinant Porcine Factor VIII (OBI-1) in Hemophilia A Patients with Alloantibody Inhibitors Directed Against Human FVIII.

Johnny Mahlangu, MD, Tatiana A. Andreeva, MD, Donald Macfarlane, MD, PhD, Mark T. Reding, MD, Christopher Walsh, MD, Bruce Ritchie, MD, Nadia Ewing, MD, Craig M. Kessler, MD, Christine Kempton, MD, Edward Libby, MD, Nadezda Zozulya, MD, Amy D. Shapiro, MD, Jean St-Louis, MD, Indira Warrier, MD, W. Keith Hoots, MD, Ralph A. Gruppo, MD, Josef N. Mueksch, MD, MBA

Blood (2007) 110 (11): 783.

https://doi.org/10.1182/blood.V110.11.783.783

Published: 2007

Journal Articles

Acquired Pure Red Cell Aplasia Associated with Alemtuzumab, Mycophenolate, and Daclizumab Immunosuppression after Pancreas Transplant.

Milena Elimelakh, MD, Vanessa Dayton, MD, Katharine S. Park, MD, Rainer W. Gruessner, MD, Angelika C. Gruessner, PhD, David E. Sutherland, MD, Barbara Bland, MS, MLIS, RN, Robert B. Howe, MD, Jo-Anne van Burik, MD, Aneel A. Asraani, MD, Mark T. Reding, MD, Tim P. Singleton, MD, Nigel S. Key, MB, FRCP

Blood (2005) 106 (11): 1058.

https://doi.org/10.1182/blood.V106.11.1058.1058

Published: 2005

NARROW

Fourth Interim Analysis of the Hem Powr Study: A Post Hoc Analysis of Real-World Effectiveness and Safety of Damoctocog Alfa Pegol in Adolescent and Older Patients with Hemophilia a

Real-World Patterns of Additional Factor Treatment Use Among Hemophilia a Patients on Regular Prophylaxis in the United States: Results from the Picnichealth Database

Become-9: A Phase 1/2 Dose Escalation and Expansion Study of be-101 for the Treatment of Adults with Moderately Severe or Severe Hemophilia B

Interim Subgroup Analysis of the Effectiveness and Safety of Damoctocog Alfa Pegol Prophylaxis in Previously Treated Patients with Hemophilia A Treated Every 5 or Every 7 Days: Results from the Real-World Observational HEM-POWR Study

Eptacog Beta Efficacy in Treating Mild or Moderate Bleeds in Target Joints of Individuals with Hemophilia A or B and Inhibitors in PERSEPT 1

A Preliminary Analysis of Athn 16: Safety of Coagulation Factor VIIa (recombinant)-Jncw for the Treatment of Bleeding Events in Patients with Congenital Hemophilia a or B with Inhibitors

Relationship between Endogenous, Transgene FVIII Expression and Bleeding Events Following Valoctocogene Roxaparvovec Gene Transfer for Severe Hemophilia A: A Post-Hoc Analysis of the GENEr8-1 Phase 3 Trial

PREDICT: A Multicenter, Prospective, Open-Label, Clinical Study Using a New Risk Score Approach to Assess the Most Appropriate Prophylaxis Regimen to Reach Favorable Outcomes in Hemophilia A, When Switching from Standard-Half-Life Products to Damoctocog Alfa Pegol

Efficacy and Safety of Bay 94-9027 Is Sustained for 5 Years: Outcomes in 33 Patients in the Protect VIII Extension Study

Decrease in Overall and Joint Bleeding Rates with Extended-Interval Dosing: > 4 Years of Bay 94-9027 Prophylaxis in the Protect VIII Extension

Maintaining Perioperative Hemostasis in Patients with Severe Hemophilia A and Inhibitors Receiving Emicizumab Prophylaxis

Barriers to the Effective Diagnosis and Management of a Bleeding Patient with Undiagnosed Bleeding Disorder Across Multiple Specialties: Results of a Quantitative Case-Based Survey.

Risk Factors for Inhibitor Development in Mild and Moderate Hemophilia A: A Case-Control Study.

Spectrum of Antiphospholipid Antibodies and Associated Thrombotic and Obstetric Events among Patients with Antiphospholipid Syndrome

A Phase II Open-Label Study Evaluating Hemostatic Activity, Pharmacokinetics and Safety of Recombinant Porcine Factor VIII (OBI-1) in Hemophilia A Patients with Alloantibody Inhibitors Directed Against Human FVIII.

Acquired Pure Red Cell Aplasia Associated with Alemtuzumab, Mycophenolate, and Daclizumab Immunosuppression after Pancreas Transplant.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only